Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediatric soft tissue sarcoma often driven by PAX3::FOXO1 or PAX7::FOXO1 fusions, for which therapy can be limited if metastatic. ARMS pathology shows pronounced cellular heterogeneity, including malignant subpopulations at distinct myogenic differentiation stages. Detailed subpopulation transcriptional programs and microenvironmental influences are of ongoing interest biologically and therapeutically.
Conflicts of Interest The authors have no direct competing interests. Charles Keller has or has had sponsored research agreements or collaborations with Roche-Genentech, Nurix Therapeutics, and Novartis. Charles Keller is also co-founder of Tio Companies and Teo Therapeutics. Artisan Biopharma is a wholly owned subsidiary of cc-TDI.
Introduction Rhabdomyosarcoma (RMS) is the most common soft tissue tumour in children and adolescents [1]. Genetically, RMS is classified into fusion-positive (FP) and fusion-negative (FN) subtypes, based on the presence or absence of characteristic fusion genes.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
